Selumetinib Boosts ORR in NF1 With Inoperable Plexiform Neurofibroma
Selumetinib led to a statistically significant and clinically meaningful improvement in ORR compared with placebo in adult patients with neurofibromatosis.
Related Articles
Restructuring endometriosis care
Women need better coordination between primary and secondary care Endometriosis affects as many as 10% of women of reproductive age, or 190 million women globally.1…
Pimicotinib Meets ORR End Point in Tenosynovial Giant Cell Tumor
Pimicotinib improved responses compared with placebo in tenosynovial giant cell tumor.
RFK Jr. and vaccine politics
Common sense thoughts on public health and conservative medicine from a family doctor in Lancaster, PA. (Move to …) Medscape Family Medicine: The Doctor Is…
177Lu-PSMA-I&T Meets rPFS End Point in PSMA+ mCRPC
177Lu-PSMA-I&T improved radiographic progression-free survival vs hormonal therapy in PSMA-positive metastatic castration-resistant prostate cancer.
Prostate radiotherapy in the era of intensified systemic treatment of metastatic prostate cancer
For men with low-volume de novo metastatic castration-sensitive prostate cancer, radiotherapy to the prostate is a standard of care option due to the significant improvement…
Refined Definition of Platinum Resistance, Novel ADCs Could Bring More Changes to Ovarian Cancer Treatment
Kathleen N. Moore, MD, MS, discusses the evolving treatment landscape of platinum-resistant ovarian cancer.
Tamibarotene Plus Azacitidine Fails to Improve CR Rates in High-Risk, RARA+ MDS
SELECT-MDS-1 will be discontinued after failing to meet its primary end point of improved CR rates with tamibarotene/azacitidine in high-risk, RARA+ MDS.
Myeloma Paper of the Day, November 22nd, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, November 22nd, suggested by Robert Orlowski / Anil Aktas Samur, Blood Journal, cancer, Giovanni Parmigiani, Hervé Avet-Loiseau,
Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer
Zolbetuximab plus chemotherapy extended PFS and OS in HER2–, locally advanced unresectable or metastatic, CLDN18.2+ gastric/GEJ adenocarcinoma.